The DOI matches its Crossref record; 1,861 of the 1,959 references it cites were found in a registry or an index; 7 of the 11 sources its claims cite were checked for support.
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.
Open accessAbstract
Objective The objective of this clinical practice guideline is to provide updated and new evidence-based recommendations for the comprehensive care of persons with diabetes mellitus to clinicians, diabetes-care teams, other health care professionals and stakeholders, and individuals with diabetes and their caregivers. Methods The American Association of Clinical Endocrinology selected a task force of medical experts and staff who updated and assessed clinical questions and recommendations from the prior 2015 version of this guideline and conducted literature searches for relevant scientific papers published from January 1, 2015, through May 15, 2022. Selected studies from results of literature searches composed the evidence base to update 2015 recommendations as well as to develop new recommendations based on review of clinical evidence, current practice, expertise, and consensus, according to established American Association of Clinical Endocrinology protocol for guideline development. Results This guideline includes 170 updated and new evidence-based clinical practice recommendations for the comprehensive care of persons with diabetes. Recommendations are divided into four sections: (1) screening, diagnosis, glycemic targets, and glycemic monitoring; (2) comorbidities and complications, including obesity and management with lifestyle, nutrition, and bariatric surgery, hypertension, dyslipidemia, retinopathy, neuropathy, diabetic kidney disease, and cardiovascular disease; (3) management of prediabetes, type 2 diabetes with antihyperglycemic pharmacotherapy and glycemic targets, type 1 diabetes with insulin therapy, hypoglycemia, hospitalized persons, and women with diabetes in pregnancy; (4) education and new topics regarding diabetes and infertility, nutritional supplements, secondary diabetes, social determinants of health, and virtual care, as well as updated recommendations on cancer risk, nonpharmacologic components of pediatric care plans, depression, education and team approach, occupational risk, role of sleep medicine, and vaccinations in persons with diabetes. Conclusions This updated clinical practice guideline provides evidence-based recommendations to assist with person-centered, team-based clinical decision-making to improve the care of persons with diabetes mellitus.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
20 Own method · 2 Partly supported · 1 Couldn’t confirm · 1 No basis given · accuracy not yet measured
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“A glucose level ≥200 mg/dL in the presence of hyperglycemia symptoms such as polyuria and polydipsia confirm the diagnosis of DM.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Evidence Base 1: How is the diagnosis of DM made and what is the current screening protocol for prediabetes and DM?
What the sources say
- Could not verifycites [6] sourceExperimental — accuracy not yet measured
The Diagnostic testing passage (page unavailable) discusses fasting glucose, HbA1c, C-peptide, and antibody tests for evaluating MODY. Neither it nor the other retrieved passages gives a ≥200 mg/dL glucose threshold with hyperglycemia symptoms for diagnosing diabetes; searches for that threshold and symptom-based criterion found no supporting passage in our copy. (LLM, conf=0.73)
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The concordance between FPG, 2-hour PG, and A1C is not perfect; thus, the diagnosis of DM requires 2 different (fasting glucose and A1C) abnormal test results, either from the same sample or 2 abnormal results on samples drawn on different days.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Evidence Base 1: How is the diagnosis of DM made and what is the current screening protocol for prediabetes and DM?
What the sources say
- Partly supportedcites [3] sourceExperimental — accuracy not yet measured
The paper’s introductory passage says diabetes diagnosis requires confirmation of an elevated glucose or HbA1c result and that two different tests above diagnostic thresholds can provide confirmation. It also says repeating the same test on a later sample is preferred, so two different tests are not required. The Discussion says guidelines were unclear about using two tests from one sample; our copy does not address the quoted exception for symptoms with glucose of at least 200 mg/dL or concordance involving 2-hour PG. (LLM, conf=0.87)
- Partly supportedcites [4] sourceExperimental — accuracy not yet measured
The paper’s opening section says that FPG or 2-hour glucose meets the usual diagnostic criteria when abnormal on more than one occasion, and that classic symptoms with a single random plasma glucose of at least 200 mg/dL are diagnostic. It does not say that confirmation requires two different tests (FPG and A1C), or that two abnormal results from the same sample suffice. Its discussion of test variability supports imperfect reproducibility, but not that specific confirmation rule. (LLM, conf=0.88)
- Partly supportedcites [5] sourceExperimental — accuracy not yet measured
The Discussion reports imperfect agreement among HbA1c, fasting plasma glucose, and 2-hour plasma glucose, and says diabetes diagnosis requires repeated measurement rather than a single test. It does not specify that the two abnormal results must be from different tests, describe the same-sample or different-day options, or state an exception for hyperglycemic symptoms with glucose of at least 200 mg/dL. (LLM, conf=0.88)
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Universal screening is recommended, as selective screening (only in women with risk factors) would miss a significant number of women with GDM and universal screening has been shown to be cost-effective compared with selective screening.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Evidence Base 1: How is the diagnosis of DM made and what is the current screening protocol for prediabetes and DM?
What the sources say
- Not matchedcites [9]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites [50] sourceExperimental — accuracy not yet measured
The Conclusions recommend GDM screening at 24–28 weeks using a 75-g OGTT. The paper does not compare universal screening with risk-factor-based selective screening or report that universal screening is cost-effective; searches for selective screening and cost-effectiveness found no such comparison. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [51] source
- Not checked — no full text of the sourcecites [52] source
- Not checked — no full text of the sourcecites [53] source
- Partly supportedcites [54] sourceExperimental — accuracy not yet measured
Section 5.2 recommends universal testing because risk-factor-based selective testing has poor sensitivity for detecting GDM. But section 5.4 says there is a lack of good evidence for the cost-effectiveness of universal testing in both high- and low-resource countries; it does not establish that universal screening is cost-effective compared with selective screening. (LLM, conf=0.90)
- Could not verifycites [55] sourceExperimental — accuracy not yet measured
The Conclusions discuss childhood glucose outcomes after maternal GDM, not whether universal screening is recommended. Searches of our copy for selective screening, missed cases, and cost-effectiveness found no passage addressing those claims. (LLM, conf=0.76)
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Real-time CGM (rtCGM) or isCGM is recommended for all persons with T1D, regardless of insulin delivery system, to improve A1C levels and to reduce the risk for hypoglycemia and DKA.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Question 3: When and how should glucose monitoring be used?
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“DM is diagnosed by using any of 3 established criteria for elevated blood glucose (BG) concentrations (Table 4). FPG ≥126 mg/dL, 2-hour PG ≥ 200 mg/dL during 75-g OGTT, and A1C ≥ 6.5% are equally appropriate for diagnostic screening (Table 4).”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Evidence Base 1: How is the diagnosis of DM made and what is the current screening protocol for prediabetes and DM?
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“For most hospitalized persons with hyperglycemia in both the intensive care unit (ICU) and non-ICU settings, a glucose range of 140 to 180 mg/dL is recommended, provided this target can be safely achieved (Table 6).”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Question 2. What are the glycemic treatment goals for persons with DM?
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Diabetic peripheral neuropathy (DPN) is a clinical diagnosis. A comprehensive differential diagnosis should be considered to rule out nondiabetic neuropathies.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Section 2: Comorbidities and Complications > Question 8: How should neuropathy be diagnosed and managed in persons with DM?
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All persons who use insulin should use CGM or perform BG monitoring (BGM) a minimum of twice daily and ideally before any insulin injection.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Question 3: When and how should glucose monitoring be used?
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“A1C should be measured at least semiannually in all persons with DM and at least quarterly in persons not at their glycemic target.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Question 3: When and how should glucose monitoring be used?
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Screening for DPN should be done at diagnosis of T2D, within 5 years of the diagnosis of T1D, and subsequently annually or whenever symptoms occur, by performing a clinical history and physical exam.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Section 2: Comorbidities and Complications > Question 8: How should neuropathy be diagnosed and managed in persons with DM?
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Continuous access to CGM for daily use is suggested for people living with T2DM at higher risk of hypoglycaemia, similar to the current CGM clinical practice guideline recommendations from Diabetes Canada 56 and the American Association of Clinical Endocrinologists. 57”
From Continuous glucose monitoring in noninsulin‐treated type 2 diabetes: A critical review of reported trials with an updated systematic review and meta‐analysis of randomised controlled trials (2025) · cites this paper as [57]
Experimental — accuracy not yet measuredIn the citing paper
“Approximately 2–5 times more patients discontinued orforglipron versus placebo due to adverse events, comparable to other GLP‐1 receptor agonists where 5%–15% discontinue in clinical trials [48].”
From Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta‐Analysis (2025) · cites this paper as [48]
In the citing paper
“Current guideline recommendations by the American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD), American College of Sports Medicine (ACSM), American Association of Clinical Endocrinology (AACE), and the American Heart Association (AHA) advocate regular resistance and aerobic exercise, as well as physical activity such as increasing daily steps to avoid sed”
From The Impact of Physical Activity in Patients With Type 2 Diabetes (2025) · cites this paper as [23]
In the citing paper
“AACE and the ADA recommend avoiding no more than 2 to 3 days between exercise routines to maintain improvement in insulin sensitivity.”
From The Impact of Physical Activity in Patients With Type 2 Diabetes (2025) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Section 2: Comorbidities and Complications > Question 6: How should DKD or CKD in DM be managed?
“An SGLT2i with proven benefit is recommended as foundational therapy for persons with T2D and CKD with eGFR ≥20 mL/min/1.73 m2 to reduce progression of CKD and risk of CVD.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Section 2: Comorbidities and Complications > Evidence Base 6: How should DKD or CKD in DM be managed?
“An SGLT2i with proven kidney protection is recommended for people with T2D who have an eGFR >25 mL/min/1.73 m2 irrespective of albuminuria to reduce risks of DKD or CKD in DM and CVD.425,443–469 In those with HF, one agent in the class, empagliflozin, can be used with an eGFR as low as 20 mL/min/1.73 m2.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Section 1: Screening, Diagnosis, Glycemic Targets, and Glycemic Monitoring
“The one-step approach uses a 2-hour 75-g oral glucose tolerance test (OGTT) after ≥8 hours of fasting with diagnostic cutoffs of one or more FPG ≥92 mg/dL, 1-hour PG ≥180 mg/dL, or 2-hour PG ≥153 mg/dL.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Section 3: Management of Prediabetes, T2D, and T1D With Selection of Glycemic Targets, Lifestyle Interventions, and Antihyperglycemic Pharmacotherapy (Insulin Therapy for all With T1D and Select Individuals With T2D); Prevention, Identification, and Treatment of Hypoglycemia; Treatment of Hospitalized Persons With DM or Those With Hyperglycemia Without Diagnosis of DM; and Women With GDM > Evidence Base 16: How should DM in pregnancy be managed?
“Glucose criteria diagnostic for GDM are an FPG >92 mg/dL, 1-hour postglucose challenge value ≥180 mg/dL, or 2-hour value ≥153 mg/dL.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Section 2: Comorbidities and Complications > Evidence Base 10: How should obesity be managed in persons with DM?
“A phase 2 study in persons with biopsy-proven NASH using a daily injection equivalent to semaglutide 2.4 g/week demonstrated 13% weight loss”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Section 2: Comorbidities and Complications > Evidence Base 10: How should obesity be managed in persons with DM?
“Subcutaneous semaglutide at the higher dose of 2.4 mg/week has been approved for chronic weight management”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Section 1: Screening, Diagnosis, Glycemic Targets, and Glycemic Monitoring
“Diagnosis of DM requires 2 abnormal test results, either from the same sample or 2 abnormal results on samples drawn on different days.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Evidence Base 1: How is the diagnosis of DM made and what is the current screening protocol for prediabetes and DM?
“the diagnosis of DM requires 2 different (fasting glucose and A1C) abnormal test results, either from the same sample or 2 abnormal results on samples drawn on different days.”
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“Adler, 2021, Reprint of: Classification of diabetes mellitus, Diabetes Res Clin Pract, 10.1016/j.diabres.2021.108972”
Cited work 10.1016/j.diabres.2021.108972 · retracted 2021-07-31 · notice 10.1016/j.diabres.2021.108972 · this paper published 2022-10
Citations
Cites
1 retracted
WITHDRAWN: Reprint of: Classification of diabetes mellitus
Adler, A., Bennett, P., Chair, S. C., Gregg, E., Venkat Narayan, K. M., Schmidt, M. I., Sobngwi, E., Tajima, N., Tandon, N., Unwin, N., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108972 · Cited by 38
Retracted(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000447068 · Cited by 11,782
Intensive insulin therapy in critically ill patients.
Van den Berghe, G., Wouters, P., Weekers, F., Verwaest, C., Bruyninckx, F., Schetz, M., Vlasselaers, D., Ferdinande, P., Lauwers, P., & Bouillon, R. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011300 · Cited by 9,977
Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., and the Northwell COVID-19 Research Consortium, Barnaby, D. P., Becker, L. B., Chelico, J. D., et al. (2020) · JAMA · doi:10.1001/jama.2020.6775 · Cited by 9,254
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Research works printed but not linked: 9
- Gillett, 2009, International Expert Committee Report on the role of the A1C assay in the diagnosis of diabetes: Diabetes care, Clin Biochem Rev, 30, 197
- 1991, VIII. Study design, progress and performance, Diabetologia, 34, 877
- Nußbaumer, 2016, Ezetimibe-statin combination therapy, Dtsch arztebl int, 113, 445
- Whelton, 2018, Hypertens (Dallas. TX, 71, e13
- 2012, KDIGO clinical practice guideline for anemia in chronic kidney disease, Kidney Int Suppl, 2, 279
- Miller, 2015, Erratum. J Fam Pract, 64, 452
- Mechanick, 2019, Endocr Pract, 25, 1346
- 2019, Long-term effects of metformin on diabetes prevention: identification of subgroups that benefited most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study, Diabetes Care, 42, 601, 10.2337/dc18-1970 · DOI · Paper page
- American Diabetes Association. Medical management of pregnancy complicated by diabetes fourth edition. Jovanovic L, ed. Alexandria, VA: American Diabetes Association, 2009.
Cited by
Sorted by citations
Items 401–494 of 494
Dietary mineral intake was correlated with seral HDL-C in patients with type 2 diabetesPreprint
Li, W., Shi, Y., Xu, D., Yang, H., Zheng, W., Wang, L., Xu, L., Lei, T., & Lu, J. K. (2025) · Research Square · doi:10.21203/rs.3.rs-6019693/v1
Cardiac Manifestations in Children of Diabetic Mothers and Fathers
Huhulea, E. N., Huang, L., Aifuwa, E., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000887
Use of telephone calls to manage glycemic control at Mexico’s northern border
Vázquez-Martínez, V. H., Martínez-Bautista, H., Morales, J. L., Garcia, F. D. G., Maldonado, D. V., & Muñoz-Villegas, P. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1420244 · Cited by 1
Mehta, A. (2025) · Journal of current cardiology. · doi:10.4103/jcc.jcc_9_25
Dysglycemia-Based Chronic Disease
Via, M. A., & Mechanick, J. I. (2025) · Springer eBooks · doi:10.1007/978-3-031-82888-1_3
Kebodeaux, C. D. (2025) · The American Pharmacists Association eBooks · doi:10.21019/9780914768098.ch11
Image Quality Assessment with Model Fusion for Ultra-widefield Fundus
Yang, B. F., Yan, Y., Liu, D., et al. (2025) · Lecture notes in computer science · doi:10.1007/978-3-031-89388-9_1
Nutritional Care Process in Hospitalized Patients with Obesity-Related Multimorbidity
Rivera-Carranza, T., Girón, A. L.-T., Mimiaga-Hernández, C., & Aguilar‐Vargas, A. (2025) · Obesities · doi:10.3390/obesities5020039
Finerenone in internal medicine and cardiology practice
Ječmenová, M. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.044
Quality indicators for pharmacist follow-up of diabetes mellitus: A RAND-modified Delphi method
Christiaens, L., Meel, L., Buyl, M., Wulf, I. D., den Bulck, S. V., Vaes, B., Raat, W., & de Putte, M. V. (2025) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-025-01942-y
Non-pharmacologic Interventions for Type 2 Diabetes
Dyke, A. V., & Lacey, C. (2025) · Springer eBooks · doi:10.1007/978-3-031-88835-9_3
Scopelliti, E. M., & Cheung, N. W. (2025) · Springer eBooks · doi:10.1007/978-3-031-88835-9_5
Al-Baaj, A. F. F., Naser, N. Z., & Ewadh, M. (2025) · Medical Journal of Babylon · doi:10.4103/mjbl.mjbl_676_25
Kovalchuk, I. V., Burlaka, I. A., & Mityuryayeva-Kornijko, I. O. (2025) · Clinical and Preventive Medicine · doi:10.31612/2616-4868.5.2025.03
Yang, J. (2025) · American Journal of Translational Research · doi:10.62347/buui5663
Nazumulkani, A., & Soukat Ali, A. (2025) · Apollo Medicine · doi:10.1177/09760016251365084
Yen, C., Li, P., Wu, C., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5397504
Importance of Educational Actions for the Prevention of Complications Arising from Diabetes Mellitus
da Silva, J. F. B., de Sousa, K. O., da Silva, M. F. B., Geraldo, A. L. Y., Filho, O. L. R., Belem, F. A. D., Sales, G. A. D. S., Alves, C. B., Voss, E. L. S., & Azevedo, E. D. J. (2025) · Revista de Gestão Social e Ambiental · doi:10.24857/rgsa.v19n8-058
Ward, K. L., Asemota, V. O., Kallop, K. P., Johnson, D. F., Ray, S. L., Fernando, S. T., & Smith, M. D. (2025) · Journal of Chiropractic Medicine · doi:10.1016/j.jcm.2025.07.002
Ortíz, A., Cebrián, A., Soto, A., Reyes, A., & Górriz, J. L. (2025) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2025.501338
“Clinical guidelines suggest the use of SGLT2 inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RA), aldosterone-reducing enzyme inhibitors (RAAS) with angiotensin-converting enzyme inhibitors (ACE inhibitors), or angiotensin II receptor blockers (ARBs 1,17,18 ).”
Bai, L., Liu, D., Su, N., Zhang, L., & Yang, Z. (2025) · Current Diabetes Reviews · doi:10.2174/0115733998359708250822102217
Kumar, A., Kapoor, A., Harikrishnan, S., et al. (2025) · Indian Heart Journal · doi:10.1016/j.ihj.2025.09.005
Yamamoto‐Kataoka, S., Tsuge, T., Kataoka, Y., Metzendorf, M., Franco, J. V. A., & Watanabe, N. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016111
Pavlova, N. I., Krylov, A. V., Bochurov, A. A., et al. (2025) · Diabetes Mellitus · doi:10.14341/dm13230
Masoud, K., & Ramchandani, N. (2025) · medtigo Journal of Medicine · doi:10.63096/medtigo3062347
“…only 5- 25% are given a diagnosis when prediabetes is identified, and 0-23% are referred for behavior intervention when prediabetes is identified (Blonde et al, 2022; Brunisholz et al., 2021; Echouffo-Tcheugui & Selvin, 2021; Evron et al., 2019; Mainous et al., 2016; Mainous et al. 2022; Nhim et…”
The Analysis of the Real People With Diabetes Study Using the NIH Feasibility Framework
Karduck, J., & Chapman‐Novakofski, K. (2025) · Topics in Clinical Nutrition · doi:10.1097/tin.0000000000000403
Nada, A. A., Metwally, A. M., Asaad, A. M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25116062
Nada, A. A., Metwally, A. M., Asaad, A. M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25116220
Peng, Y., Duan, J., Hou, J., Xu, N., Wu, J., Bao, X., Yao, Q., & Li, Y. (2024) · Figshare · doi:10.6084/m9.figshare.25397496
Ventura, A. C., Franch‐Nadal, J., & Ortega, M. (2025) · Diabetes práctica · doi:10.52102/diabet/pract.2025.1.art2
Chen, F., Pan, H., Wang, Y., Liu, J., Wang, Y., & Wu, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-33822-w
“…nurse advises the patient to manage his blood glucose scientifically, emphasizing the rate and extent of blood glucose reduction, while also focusing on preventing episodes of low blood glucose levels 36,38,39 Modelling The nurse shares information about authentic clinical cases with the patient.”
Taşkın, S. N., Doğan, V., Acungil, Z. K., Cinni, R. G., Bilge, S., Gök, Ş. Ü., Aydoğan, L., Benli, İ., Kara, A. E., İnce, D. A., et al. (2026) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-025-02178-2
Reginia, A., Mazur, A., Bąba-Kubiś, A., Jabłoński, M., Sołtysiński, M., Samochowiec, J., & Kucharska–Mazur, J. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1741046
Canbolat, O., Şirali, S. K., & Bulucu, M. F. (2026) · The European Research Journal · doi:10.18621/eurj.1795033
Educational game on prevention and early diagnosis of type 2 diabetes mellitus for students
da Silva, Á. M. B., Santos, I. T. D. S., Matias, M. E. B., Soares, G. H. D. S., Costa, I. P., Mágero, F. R. L., Padilha, F. M. Q. D. H., & Neto, G. H. F. (2026) · Revista Brasileira de Educação Médica · doi:10.1590/1981-5271v50.1-2025-0041 · Cited by 1
Cardiovascular risk equations in type 1 diabetes: from generic models to personalized prediction
Serés‐Noriega, T., Lafarga, I. A., Perea, V., Viñals, C., & Amor, A. J. (2026) · Annals of Medicine · doi:10.1080/07853890.2026.2642404 · Cited by 2
Ramar, V. A., Kolli, Y. K., Kushala, K., Induru, V., Radhakrishnan, P., & Kumar, S. K. P. (2025) · Asian Conference on Intelligent Technologies (ACOIT) · doi:10.1109/acoit66109.2025.11436948
“[3] revised the American Association of Clinical Endocrinology clinical practice guidelines, which contained 170 evidence-based recommendations for general diabetes care managing comorbidities, screening, treatment, and new topics such as social determinants and virtual care.”
White, A. A., & Wisse, B. E. (2026) · Applied Clinical Informatics · doi:10.1055/a-2838-8292
Taylor, R., Burrows, T. L., Bone, E. E., Asher, R. C., & Collins, C. E. (2026) · Nutrition Reviews · doi:10.1093/nutrit/nuag033
Suva, M. A. (2026) · Archives of Medicine and Health Sciences · doi:10.4103/amhs.amhs_121_25
Marineau, E. J., & Dubovetsky, D. (2026) · JAPhA Practice Innovations · doi:10.1016/j.japhpi.2026.100111
Peled, T., Ben-Ami, T., Helman, S., Lando, M. B., Grisaru‐Granovsky, S., & Rottenstreich, M. (2026) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.70998
Ueda, K., Saito, R., Matsunaga, A., Sonoda, T., Kawaguchi, M., Kaeriyama, S., Sato, S., Zenimaru, Y., Ikawa, M., & Harada, N. (2026) · Diabetology · doi:10.3390/diabetology7040074
“Therefore, the American Diabetes Association (ADA) and the American Association of Clinical Endocrinology (AACE) guidelines recommend the relaxation of treatment goals based on comorbidities, physical function, and cognitive function in elderly individuals with diabetes [16,17].”
Global challenges in chronic disease detection: Multidisciplinary approaches
Vishwakarma, R. K., Gautam, P., Sahu, M., Nath, G., & Yadav, B. S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33263-0.00012-7
Endocrinologist-led glucose management in the emergency ICU: a retrospective before-after study
Zhang, L., Zhao, Z.-S., Gu, C.-X., Ma, Y., & Yu, X. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1790977
Shrikhande, A., Hall, J., Orbuch, I., Advincula, A., Wolfrum, K., Sarrel, S., Drummond, J., Rampally, L., Gonzalez-Engle, J., Ross, J., et al. (2026) · Women's Health · doi:10.1177/17455057261440214 · Cited by 1
Tkaczyk, F. M. (2026) · Reports — Medical Cases Images and Videos · doi:10.3390/reports9020142 · Cited by 1
Pollard, K. J., Ames, M. L., Anderson, K., Gobble, J. E., Moore, S., Patel, P. M., Pauly, K. R., Staffier, K. L., Tondapu, P., & Karlsen, M. C. (2026) · American Journal of Lifestyle Medicine · doi:10.1177/15598276261438370
Camargo, T. M., Siqueira, B. A., Marques, L. F. A., et al. (2026) · Diabetic Medicine · doi:10.1111/dme.70349
Aldakhil, R., Greenfield, G., Kerr, G. K., Hayhoe, B. W. J., Kunz, H., Valabhji, J., Majeed, A., & Neves, A. I. A. (2026) · medRxiv · doi:10.64898/2026.05.07.26352666
Xu, Y., Zeng, S., Xi, Y., et al. (2026) · BMC Nephrology · doi:10.1186/s12882-026-05035-4
“…from trials has been robust, it is necessary to know how finerenone fares in routine clinical practice as trials possess rigorous inclusion/exclusion criteria, which create a highly selected group of patients who may fail to reflect the heterogeneity of patients in real-world practice [16].”
Fridell, J. A., Dunn, T. B., Oram, R. A., Sadhu, A., Spaggiari, M., Dib, Y. E., & Odorico, J. S. (2026) · Transplantation · doi:10.1097/tp.0000000000005757
Self-citationChen, S., Xu, B., & Lu, M. (2026) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514261453485 · Cited by 1
“2,5,6 These measures provide a practical basis for routine care, but they do not fully explain why intolerance develops, persists, or becomes dose-limiting in some patients despite apparently similar treatment conditions.”
InfluentialZhang, B.-B., Li, C.-F., & Fan, H. (2026) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1080/15412555.2026.2672702
Diabetic retinal disease: A sensory neuropathy
Gardner, T. W., & Malik, R. A. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-443-22212-2.00001-x
Self-citationYan, M., Yang, H., Cui, D., & Zhang, Y.-S. (2026) · World Journal of Psychiatry · doi:10.5498/wjp.120241
Yoldi-Vergara, C., Montesinos, S. P., Rodriguez-Rodríguez, S., Morado, A. M. C., Cuervo, P. M., Vázquez, M. B., Girardot, S. K., Jansà, M., Garrido, M. D. R., Alba, M. P. P., et al. (2026) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2026.501851
Costa, A. G., Ribeiro, N. A. M., Dourado, A. D., Duarte, M. L., & Ladeia, A. M. T. (2026) · International Journal of Cardiovascular Sciences · doi:10.36660/ijcs.20240161
Review of the Insulin Sensitivity Factor Calculator
Lundholm, M. D. (2026) · Evidence to Action Official Journal of MDCalc · doi:10.65357/001c.162489
Gautam, R., Wang, H., Zhou, B., Neba, R. A., & Sambamoorthi, U. (2026) · Alcohol and Alcoholism · doi:10.1093/alcalc/agag045
Association Between Longitudinal Time in Range and Albuminuria in Insulin-Treated Diabetes
Yoshimura, K., Miyazaki, Y., Kobayashi, M., Nakatsuji, M., Saito, S., Nishikage, S., Yamamoto, A., Takayoshi, T., Asahara, S., Ogawa, W., et al. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261462229
Sawyer, A., Wilmot, E. G., Do, D., Miller, K. M., Ly, T. T., & Forlenza, G. P. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261456826 · Cited by 2
Hsieh, H., Huang, Y., Chang, Y.-W., & Liao, W. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261460619
Qian, J., He, Q., Miao, M., Ni, W., & Ma, Y. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1803501
Efficacy and Safety of Ion Channel Modulators in Painful Diabetic Neuropathy
Li, D., Ouyang, L., Chen, Z., Long, Y., & Deng, G. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71053
“Gabapentinoids, such as pregabalin and gabapentin, are recommended for the treatment of PDN by the guidelines of the American Academy of Neurology (AAN), American Diabetes Association (ADA), and American Association of Clinical Endocrinology (AACE) [16–18].”
Prognostic Factors in Acute Ischemic Stroke With a Decreased Estimated Glomerular Filtration Rate
Kim, C. H., Lee, H. U., Shin, B. S., et al. (2026) · Brain and Behavior · doi:10.1002/brb3.71589
When headache signals hypoglycemia: Clinical recognition and management
Burroughs, B. T. (2026) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2026.07.005
London, B., Hornung, L. N., Elder, D. A., & TELLEZ, S. E. (2026) · Journal of Diabetes Science and Technology · doi:10.1177/19322968261465344
Lalani, B., Penno, R., Bay, R. C., & Lalani, A. (2026) · Journal of Diabetes Science and Technology · doi:10.1177/19322968261467050
Dockery, A., Abraha, G., Musa, M. R. O., Ariahu, N., & Nnorom, F. I. (2026) · Cureus · doi:10.7759/cureus.113156
“Comorbidities such as diabetes mellitus may further complicate their care and increase their chances of dying [13, 14].”
Bujdei-Tebeică, I., Stoian, A. P., Mihai, D. A., Ștefan, S., & Serafinceanu, C. (2026) · Clinics and Practice · doi:10.3390/clinpract16080141 · Cited by 1
Lalani, B., Abusamaan, M. S., Demidowich, A. P., Zilbermint, M. F., Sarkar, S., & Mathioudakis, N. N. (2026) · Journal of Diabetes Science and Technology · doi:10.1177/19322968261468379
Yang, S., Zhou, H., Liao, X., Lin, Y., & Liou, J. J. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1899142
Petridis, S. F., Olayiwola, A., Vendrame, F., Baidal, D. A., Burke, G. W., Pugliese, A., & Varghese, R. T. (2026) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2026.08.018
Buckley, C. T., Mulherin, D. W., & Cogle, S. V. (2026) · Nutrition in Clinical Practice · doi:10.1002/ncp.70175
“13,52 More specifically, the role of PN in clinical outcomes associated with hypoglycemia has not been determined.”
Jain, H., Sarikonda, A., Ye, E., Tang, A. R., Zakieh, O., Vanleuven, J., Lyons, A. T., Sundrani, S. C., Montgomery, A., Navid, W., et al. (2026) · Operative Neurosurgery · doi:10.1227/ons.0000000000002177
Virtual Diabetes Optimization Program (VDOP) for Veterans With Uncontrolled Diabetes
ADEL, T., Hansen, J. M., TAXMAN, J., Reetz-Norton, M., Johnson, C., Ljubic, N., Ash, G. I., Whittle, J., & Mendez, C. E. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doc26-0020
Puryear, M., James, A., Bagnola, A. J., McLaughlin, E., Snider, M. J., & Dungan, K. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.08.011
Stress-Induced Hyperglycemia in General Surgery
Zaino, J., Diaz-Sarmiento, V. S., Idrees, T., & Umpierrez, G. E. (2026) · Clinics in Perioperative Nursing Care · doi:10.1016/j.pernc.2026.05.005
Self-citationContinuous glucose monitoring devices in hospitalized pediatric patients
Mensah, I. K., & Farnsworth, C. W. (2026) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2026.2722682
Insulin Resistance Management and Glycemic Control
Bansal, P., Deupa, H., Shankar, P., et al. (2026) · Springer eBooks · doi:10.1007/978-981-92-3294-9_8
Feigin, E., & Zaitoon, H. (2026) · Diabetology · doi:10.3390/diabetology7090171
Ray, S. D., He, L. L., Rottersmann, S., Hand, C., Leo, M. D., Chunilall, A., Gray, I. G., Siu, N. T., Jong, S., Sirois, N., et al. (2026) · Diabetology · doi:10.3390/diabetology7090176 · Cited by 3
Obesity-Related Tendon Pathology: Cardiometabolic Mechanisms, Clinical Implications, and Management
Zhao, H., & Lu, J. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00759-8
“In patients with diabetes or peripheral or autonomic neuropathy, exercise progression may require closer monitoring of pain, balance, skin integrity, cardiovascular responses, and overall tolerance [96].”
InfluentialAkers, K., Nguyen, K., Frederickson, A. M., Bash, L. D., Ke, X., & Goodman, S. G. (2026) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2026.200710
Ji, K., Zhang, D., Zhao, Y., Zeng, Z., Jiang, M., & Zhang, J. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101793
Badran, H. M., Mohamed, M. K. G., Soltan, G. M., et al. (2026) · Romanian Journal of Cardiology · doi:10.2478/rjc-2026-0024
Kan, M., Ter, Z. Y., Sofian‐Seng, N., Chang, L. S., Wang, S., Babji, A. S., & Lim, S. J. (2026) · Food Bioscience · doi:10.1016/j.fbio.2026.110061
Ahmed, M. J., Ahmad, A. M., Naqvi, S., Ahmed, K., Ahmed, A., & Naqvi, Z. (2026) · Cureus · doi:10.7759/cureus.116699
Hoog, M. M., Vallarino, C. R., Maldonado, J. M., Grabner, M., Teng, C., Terrell, K. A., & Richard, E. L. (2026) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2026.32.10.1173
Tahir, A., Khan, K., Hasan, M. K., Jamil, H., Jamil, T., & Hakeem, S. (2026) · Journal of Basic & Clinical Medical Sciences · doi:10.58398/0002.000034
Morris, D., Cutshall, B. T., Watson, H., Wolfe, E. D., Wentzler-Lara, L., & Wells, D. A. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02738-5
“Additionally, the American Association of Clinical Endocrinology does not acknowledge a preferred basal insulin dosing frequency [3 ].”
Suksatan, W. (2026) · Journal of Medicine Surgery and Public Health · doi:10.1016/j.glmedi.2026.100257
Metadata
- Authors
- Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., Gardner, T. W., Garg, R., Garvey, W. T., Hirsch, I. B., Hurley, D. L., Izuora, K., Kosiborod, M., Olson, D., Patel, S. B., Pop-Busui, R., Sadhu, A. R., Samson, S. L., Stec, C., Tamborlane, W. V., Tuttle, K. R., Twining, C., Vella, A., Vellanki, P., & Weber, S. L.
- Affiliations
- Ochsner Health System (US)
- Emory University (US)
- Central Michigan University (US)
- Washington University in St. Louis (US)
- University at Buffalo, State University of New York (US)
- Cedars-Sinai Medical Center (US)
- The University of Texas at San Antonio (US)
- Scripps Whittier Diabetes Institute (US)
- University of Michigan (US)
- University of California, Los Angeles (US)
- University of Alabama at Birmingham (US)
- University of Washington (US)
- Mayo Clinic (US)
- University of Nevada, Las Vegas (US)
- Saint Luke's Hospital (US)
- Colorado Health Foundation (US)
- University of Cincinnati Medical Center (US)
- Houston Methodist (US)
- Mayo Clinic in Florida (US)
- American Association of Clinical Endocrinologists (US)
- Yale University (US)
- Maine Medical Center (US)
- Prisma Health (US)
- ORCID
- Blonde, Lawrence
- Umpierrez, Guillermo E.
- McGill, Janet B.
- Berga, Sarah L.
- Bush, Michael
- Chandrasekaran, Suchitra
- DeFronzo, Ralph A.
- Einhorn, Daniel
- Galindo, Rodolfo J.
- Gardner, Thomas W.
- Garg, Rajesh
- Garvey, W. Timothy
- Hirsch, Irl B.
- Hurley, Daniel L.
- Izuora, Kenneth
- Kosiborod, Mikhail
- Patel, Shailendra B.
- Sadhu, Archana R.
- Samson, Susan L.
- Tamborlane, William V.
- Tuttle, Katherine R.
- Vella, Adrian
- Vellanki, Priyathama
- Venue
- Endocrine Practice
- Publisher
- Elsevier BV
- Published
- 2022-10
- Volume
- 28
- Issue
- 10
- Pages
- 923-1049
- ISSN
- 1530-891X (ISSN-L)
- PMC
- PMC10200071
- OpenAlex
- W4291397630
- Cited by
- 507
- References
- 1,959
- Citations by year
- 2026: 95 · 2025: 119 · 2024: 150 · 2023: 134 · 2022: 9
- FWCI
- 76.49
- Type
- journal article
- Language
- en
- Update notices
- erratum (2023-01-01)
- Open access
- bronze
- doi.org
- Locations
- Endocrine Practice (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (K23DK123384, P30DK111024)
- National Institute of Diabetes and Digestive and Kidney Diseases
- BP
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- diabetes mellitus, comprehensive diabetes care, glycemic targets, blood glucose monitoring, diabetes complications, obesity, bariatric surgery, hypertension, dyslipidemia, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, cardiovascular disease, prediabetes, type 2 diabetes, type 1 diabetes, insulin therapy, hypoglycemia, diabetes in pregnancy, diabetes education, infertility, dietary supplements, social determinants of health, virtual care, cancer risk, pediatric diabetes care, depression, sleep medicine, team-based care
- MeSH terms
- Child, Diabetes Mellitus, Type 2, Endocrinology, Female, Humans, Hypoglycemic Agents, Insulin, Pregnancy, United States, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-25 (prompt extract-v1).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
